Search

Your search keyword '"Mirabel, X."' showing total 605 results
Start Over Author "Mirabel, X."
605 results on '"Mirabel, X."'

107. VISMONEO - a phase II study assessing vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma - Patients characteristics

Author

Basset-Seguin, N., primary, Dupuy, A., additional, Saiag, P., additional, Dalac-Rat, S., additional, Guillot, B., additional, Routier, E., additional, Leccia, M.T., additional, Duhamel, A., additional, Mirabel, X., additional, Benbouta, I., additional, Mirakovska, L., additional, Meddour, D., additional, Dib, M., additional, Mahmoudi, A., additional, Guerreschi, P., additional, and Mortier, L., additional

Published
2016
Full Text
View/download PDF

108. Clinical implementation of a Monte Carlo based treatment plan QA platform for validation of Cyberknife and Tomotherapy treatments

Author

Reynaert, N., primary, Demol, B., additional, Charoy, M., additional, Bouchoucha, S., additional, Crop, F., additional, Wagner, A., additional, Lacornerie, T., additional, Dubus, F., additional, Rault, E., additional, Comte, P., additional, Cayez, R., additional, Boydev, C., additional, Pasquier, D., additional, Mirabel, X., additional, Lartigau, E., additional, and Sarrazin, T., additional

Published
2016
Full Text
View/download PDF

114. PO-0950: QA and dummy-run results of the TRENDY randomized trial on SBRT vs. chemoembolization for HCC

Author

Habraken, S.J.M., primary, Heijmen, B.J.M., additional, Buijsen, J., additional, Verbakel, W.F.A.R., additional, Haasbeek, C.J.A., additional, Ollers, M.C., additional, Westerveld, G.H., additional, Van Wieringen, N., additional, Reerink, O., additional, Seravalli, E., additional, Braam, P.M., additional, Wendling, M., additional, Lacornerie, T., additional, Mirabel, X., additional, Weytjens, R., additional, Depuydt, L., additional, Lang, S., additional, Riesterer, O., additional, Haustermans, K., additional, Depuydt, T., additional, and Méndez Romero, A., additional

Published
2016
Full Text
View/download PDF

122. Erratum à « Prise en charge thérapeutique des patients atteints d’un mélanome cutané métastatique : recommandations nationales françaises » [Ann. Dermatol. Venereol. 141 (2014) 111–21]

Author

Leccia, M.-T., primary, Planchamp, F., additional, Sassolas, B., additional, Combemale, P., additional, Modiano, P., additional, Bedane, C., additional, Cupissol, D., additional, Derrey, S., additional, Dygai-Cochet, I., additional, Lamant, L., additional, Lubrano, V., additional, Mirabel, X., additional, Mourrégot, A., additional, Rougé Bugat, M.-E., additional, Siegrist, S., additional, Thariat, J., additional, Tiffet, O., additional, Truc, G., additional, Verdoni, L., additional, and Mazeau-Woynar, V., additional

Published
2014
Full Text
View/download PDF

124. First-line and second-line systemic treatments of patients with metastatic cutaneous melanoma (without brain metastasis) : French national guidelines

Author

Cupissol, D., primary, Sassolas, B., additional, Combemale, P., additional, Modiano, P., additional, Bedane, C., additional, Derrey, S., additional, Dygai-Cochet, I., additional, Lamant, L., additional, Lubrano, V., additional, Mirabel, X., additional, Mourrégot, A., additional, Rougé Bugat, M. -E., additional, Siegrist, S., additional, Thariat, J., additional, Tiffet, O., additional, Truc, G., additional, Verdoni, L., additional, Mazeau-Woynar, V., additional, Planchamp, F., additional, and Leccia, M. T., additional

Published
2014
Full Text
View/download PDF

134. Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients).

Author

Cordoba, A., Escande, A., Lopez, S., Mortier, L., Mirabel, X., Coche-Déqueant, B., and Lartigau, E.

Subjects
PENILE cancer, INTERSTITIAL brachytherapy, LOW dose rate brachytherapy, SQUAMOUS cell carcinoma, FOLLOW-up studies (Medicine), PATIENTS, CANCER treatment, CLINICAL trials, COMPARATIVE studies, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, PROGNOSIS, RADIATION doses, RADIOISOTOPE brachytherapy, RESEARCH, SURVIVAL, TIME, TUMOR classification, PENILE tumors, EVALUATION research
Abstract

Purpose/objectives: The aim of this study is to analyze the results of exclusive interstitial brachytherapy (IBT) as a conservative approach in the treatment of penile cancer confined to the glans or the shaft with long-term follow-up in a single institution.Materials/methods: Between July 1992 and November 2013, 73 consecutive patients with non-metastatic invasive penile cancer were treated by Low dose rate (LDR) IBT in our institution. The localization of the primary lesion was glands in 67 patients (91.8 %) and shaft in 6 patients (8.2 %). All 73 patients presented with squamous cell carcinoma with grades of differentiation as follows: 34 patients with grade 1 (44.7 %), 9 patients with grade 2 (11.8 %), 9 patients with grade 3 (11.8 %) and 21 patients unknown (28.8 %). Six patients (7.8 %) presented with in situ carcinoma, 55 patients (75,3 %) presented with T1, 11 patients (15 %) presented with T2, and one patient (1.3 %) presented with Tx. Inguinal nodal dissection was performed in 29 patients (38.2 %); 13 patients (17.8 %) presented with histologically confirmed positive ganglion. After circumcision, IBT was performed using a hypodermic needle. The median dose delivered was 60 Gy (range, 40 to 70 Gy). The median activity of the iridium-192 wire was 1.12 mCi/cm, and the median reference isodose rate was 0.4 Gy/h (range, 0.2-1.2). Patients with histological inguinal metastases received external beam radiotherapy to the selected inguinal affected area with a median dose of 45 Gy (30-55 Gy).Results: The median follow-up time was 51.8 months (range 34.4 to 68.7). The 5-year overall survival was 82.0 %, with eight deaths from cancer and five non-cancer-related deaths. Disease-specific survival was 91.4 %, relapse-free survival was 64.4 %, and local relapse-free survival as 74 %. Total or partial penile preservation was 87.9 % at 5-years. Complications rates at 5 years were 6.6 % urethral stenosis (five patients), two patients (2.6 %) with pain related to sexual intercourse and four patients (5.3 %) with dysuria grade 2. Five patients (6.8 %) required penile amputation for necrosis.Conclusions: IBT provides good local control with organ preservation, excellent tolerance and low complication rates in early-stage penile cancers. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results